1Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s[J]. Nature, 1993,362 : 801-809.
2Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy[J]. J Cell Cardiol, 1999,31:61-74.
3John M. Role of argiolension-convertion enzyme inhibition in reversal of endiothelial dysfunction in coronary artery disease[J]. Am J Med,1998,105:405.
4Bergmann S, Siekmerier R, Mix C, et al. Even moderate cigarette smoking influences the pattern of circulating monocytes and concentration of SICAM-1[J]. Respir Physiol, 1998,114,269-275.
5Feron O, Dessy C, Monitte S, Desager JP, et al. Hypercholestrolernia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase[J].J Clin Invest, 1999,103:897-905.
6Tanner FC, Boulanger CM, Luscher TF. Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction : alterations in hypercholesterolemia and atherosclerosis[J]. Serain Thromb Hemost, 1993,19:167-175.
7Laroia ST, Ganti AK, Laroia AT, et al. Endothelium and lipid metabolism: the current understanding [J]. Intern J Cardiol, 2003,88:1-9.
8Lundman P, Eriksson M, Schenck-gustafsson K, et al. Transient triglyceridemia decreases vascular reactivity in young,healthy men without risk factors for heart diease[J]. Circulation, 1997,96:3226-3228.
9Drexler H, Horning B. Endothelial dysfunction in human disease [J]. J Mol Cell Cardiol, 1999,31:51-60.
10Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans [J]. Circulation, 1997, 95 : 5, 1191-1121.
